The abstract is read at the publisher; the summary is JClub's.
Dual inhibition of mTORC1/2 and Scd1 creates a synthetic-lethal vulnerability in pancreatic ductal adenocarcinoma, preventing adaptive PI3K/Akt rebound and improving anti-PD-1 synergy.
- Why it matters: mTOR inhibitors have limited efficacy in PDAC because tumors rapidly adapt, and it is unclear how mTORC1 versus mTORC2 drive distinct resistance programs.
- What they did: Using inducible genetically engineered mouse models and matched organoids, the study mapped complex-specific adaptations and then tested pharmacologic co-inhibition of mTORC1/2 with Scd1.
- The result: mTORC1 loss delayed progression but triggered PI3K/Akt hyperactivation, while mTORC2 loss disrupted sphingolipid synthesis and increased saturated lipid rafts, together making Scd1 dependency targetable and enhancing interferon-γ responses with anti-PD-1.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.